Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant

• Status: Completed
• Trial end date: 2013-02-12

Summary

RATIONALE: Rasburicase may be an effective treatment for graft-versus-host disease caused by a donor stem cell transplant.

PURPOSE: This clinical trial is studying how well rasburicase works in preventing graft-versus-host disease in patients with hematologic cancer or other disease undergoing donor stem cell transplant.

• Phase: Phase 1

Details

• Lead Sponsor: Massachusetts General Hospital
• Treatments: Allopurinol; Busulfan; Cyclophosphamide; Cyclosporine; Cyclosporins; Etoposide; Fludarabine; Methotrexate; Rasburicase; Sirolimus; Tacrolimus